SCHEMBL2934019

SCHEMBL2934019

NC(=O)c1ccc(Nc2cncc(-c3cc4ccccc4[nH]3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 2/20 0.47
RAF1 P04049 1/20 0.47
SIRT2 Q8IXJ6 3/20 0.43
SIRT1 Q96EB6 3/20 0.43
SIRT3 Q9NTG7 3/20 0.43
SYK P43405 4/20 0.42
RIPK1 Q13546 1/20 0.40
ROCK1 Q13464 1/20 0.40
GAK O14976 1/20 0.40
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
FLT3 P36888 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MARK1 Q9P0L2 1/20 0.40
STK17A Q9UEE5 1/20 0.40
ATP4A P20648 2/20 0.40
ATP4B P51164 2/20 0.40
JAK3 P52333 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.40
TBK1 Q9UHD2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL2933253 0.96 BRAF (0.47) BRAFRAF1SIRT2SIRT1SIRT3
SCHEMBL2933256 0.84 BRAF (0.57) BRAFITK
SCHEMBL2932836 0.83 ITK (0.41) BRAFITK
SCHEMBL2928571 0.81 BTK (0.53) BRAFRIPK1KITFLT3JAK3
SCHEMBL2927043 0.79 HCAR3 (0.48) BRAFSYKTBK1ITKGSK3B
SCHEMBL2928708 0.79 BRAF (0.39) BRAFTBK1ITK
SCHEMBL2931626 0.79 BRAF (0.39) BRAFSYKMKNK2IRAK4TBK1
Acetic Acid SCHEMBL2934985 0.78 BTK (0.52) BRAFRIPK1FLT3MAPK10LRRK2
SCHEMBL27745009 0.78 BRAF (0.36) BRAFSYKITKGSK3B
SCHEMBL27744978 0.78 BRAF (0.36) BRAFSYKITKGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP claimed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US claimed
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 BRAF 524/4885RAF1 122/4885SIRT2 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.